Expectations trend
FY2028 · fiscal year ending 2028-06-30 · fmp
$0.01 → $0.01 · observed estimates
IPERIONX LTD (IPX)
NASDAQMaterialsOther Precious MetalsSnapshot 2026-11-05
$14.22-6.51%
Close 2026-11-05 · 1-day change
NASDAQMaterialsOther Precious MetalsSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 6, 2026.
Next-FY EPS estimate change · 30 days
0.01 → 0.01 EPS · FY ending Jun 30, 2028 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
| Measure / period | Management expectations | Analyst expectations |
|---|---|---|
| Quarter ending 2026-12-30 | ||
| Revenue | No revenue guidance available | 4.35M |
| EPS | No EPS guidance available | -0.06 |
| Annual ending 2027-06-30 | ||
| Revenue | No revenue guidance available | 21.54M |
| EPS | No EPS guidance available | -0.289 |
| Annual ending 2028-06-30 | ||
| Revenue | No revenue guidance available | |
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Lower feedstock costs for titanium production | Strong demand for titanium and supportive US policies could drive growth. | Intact | fails to achieve a 15% reduction in feedstock costs by FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-06-30 · fmp
$0.01 → $0.01 · observed estimates
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
IPX is a smaller-cap, cyclical Materials name, so its results may be more exposed to economic shifts than those of more stable businesses. The multi-year view is unclear because recent financial-performance history is not sufficient to assess the thesis.
The evidence does not include valuation or market-expectations data, so whether IPX is cheap or expensive versus peers cannot be assessed. Its recent price reaction was muted, but that alone does not show what expectations are priced in.
Near term, the sector backdrop is a tailwind, but the evidence does not establish IPX's own recent operating direction. The stated miss probability is 28%, with smaller-company risk and a deep miss in its recent history as cautions.
A favorable scenario depends on Materials bellwethers HL, SBSW, and SSMR continuing to beat earnings and raise guidance. The tailwind could fade if they miss or guide lower, while further weakening in the jobs report could increase recession concerns and weigh on cyclical businesses.
Over the next 1 to 3 years, the long-term thesis remains uncertain: sector momentum is supportive, but company-specific evidence is thin and the risk profile is high. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
90.8M |
| EPS | No EPS guidance available | 0.011 |
|---|
Management figures unavailable.
| Recent validation of its production system enhances its market position. |
| Intact |
| failure to achieve production ramp-up by Q2 2027 |
Validation achieved Sep 2026 vs Q2 2027 target IperionX validated continuous titanium production system in Sep 2026; Army award expands capacity; demand supported by US policy. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Strong demand for titanium products | Strong demand for titanium and supportive US policies could drive growth. | Under Pressure | falls below 10% YoY growth in titanium-related revenue | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Oct 6, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.09B → $0.09B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-10-05 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-06 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-07 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-08 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-09 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-10 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-11 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-12 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-13 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-14 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-15 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-16 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-17 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-18 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-19 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-20 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-21 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-22 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-23 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-24 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-25 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-26 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-27 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-28 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-29 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-30 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-10-31 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-11-01 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-11-02 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-11-03 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-11-04 | $0.01 | $90,803,600 | 1 / 3 |
| 2026-11-05 | $0.01 | $90,803,600 | 1 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.